医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

The Global Gaucher Disease Market Will Exhibit Moderate Growth from 2014 to 2019: TechNavio

2015年03月16日 PM11:35
このエントリーをはてなブックマークに追加


 

LONDON

TechNavio has announced the publication of a new market research report on the Global Gaucher Disease Market, which is expected to grow at a CAGR of 7.60 percent from 2014-2019.

About the Report

The latest report by TechNavio focuses on diseases that affect a small percentage of the population and are backed by few marketed drugs. Regions like US and European Union have a provision for ‘orphan drug designation’, where orphan drugs enjoy protocol assistance and a 10 year market exclusivity.

“Market exclusivity is a commercially beneficial provision that is increasingly attracting pharmaceutical companies to work for orphan diseases,” says Faisal Ghaus, Vice President of TechNavio.

“The entry of generic drugs is barred for the duration of market exclusivity, so as to protect the market sales of an orphan drug.”

Furthermore, the report emphasizes the increasing regulatory assistance in emerging nations. Developing countries are making various legislative changes to promote research on orphan diseases. These countries are also working towards providing incentives like reimbursements to pharmaceutical manufacturers to encourage research in this area.

“Taiwan and South Korea have already implemented regulations regarding orphan drug designation while countries like India are still working on this area,” says Ghaus.

Key Information Covered in the Report:

  • Market segmentation, size and forecast through 2019
  • Market Growth Drivers:
    • Special Provisions for Orphan Drugs
    • For a full detailed list, view our report.
  • Market Challenges:
  • Market Trends:
    • Regulatory Assistance in Emerging Nations
    • For a full detailed list, view our report.
  • Key Vendors:
    • Actelion Pharmaceuticals Ltd.
    • Genzyme Corp.
    • Pfizer Inc.
    • Shire plc
  • Other Prominent Vendors:
    • Amicus Therapeutics
    • Belrose Pharma
    • Bionaturis
    • ISU Abxis

TechNavio currently has more than 3000 market research reports on a huge range of topics, including 200+ reports on the diseases market:

If you are interested in more information, please contact our media team at media@technavio.com.

CONTACT

TechNavio Research
Jes Ellacott
US: +1-630-333-9501
UK:
+44 208 123 1770
Media & Marketing Executive
www.technavio.com
media@technavio.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent